Olivera Story Jovanova,Ivana Nedeljkovic,Derek Spieler,Rosie M Walker,Chunyu Liu,Michelle Luciano,Jan Bressler,Jennifer Brody,Amanda J Drake,Kathryn L Evans,Rahul Gondalia,Sonja Kunze,Brigitte Kuhnel,Jari Lahti,Rozenn N Lemaitre,Riccardo E Marioni,Brenton Swenson,Jayandra Jung Himali,Hongsheng Wu,Yun Li,Allan F McRae,Tom C Russ,James Stewart,Zhiying Wang,Guosheng Zhang,Karl-Heinz Ladwig,Andre G Uitterlinden,Xiuqing Guo,Annette Peters,Katri Räikkönen,John M Starr,Melanie Waldenberger,Naomi R Wray,Eric A Whitsel,Nona Sotoodehnia,Sudha Seshadri,David J Porteous,Joyce van Meurs,Thomas H Mosley,Andrew M McIntosh,Michael M Mendelson,Daniel Levy,Lifang Hou,Johan G Eriksson,Myriam Fornage,Ian J Deary,Andrea Baccarelli,Henning Tiemeier,Najaf Amin

Abstract:Importance: Depressive disorders arise from a combination of genetic and environmental risk factors. Epigenetic disruption provides a plausible mechanism through which gene-environment interactions lead to depression. Large-scale, epigenome-wide studies on depression are missing, hampering the identification of potentially modifiable biomarkers. Objective: To identify epigenetic mechanisms underlying depression in middle-aged and elderly persons, using DNA methylation in blood. Design, setting, and participants: To date, the first cross-ethnic meta-analysis of epigenome-wide association studies (EWAS) within the framework of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium was conducted. The discovery EWAS included 7948 individuals of European origin from 9 population-based cohorts. Participants who were assessed for both depressive symptoms and whole-blood DNA methylation were included in the study. Results of EWAS were pooled using sample-size weighted meta-analysis. Replication of the top epigenetic sites was performed in 3308 individuals of African American and European origin from 2 population-based cohorts. Main outcomes and measures: Whole-blood DNA methylation levels were assayed with Illumina-Infinium Human Methylation 450K BeadChip and depressive symptoms were assessed by questionnaire. Results: The discovery cohorts consisted of 7948 individuals (4104 [51.6%] women) with a mean (SD) age of 65.4 (5.8) years. The replication cohort consisted of 3308 individuals (2456 [74.2%] women) with a mean (SD) age of 60.3 (6.4) years. The EWAS identified methylation of 3 CpG sites to be significantly associated with increased depressive symptoms: cg04987734 (P = 1.57 × 10-08; n = 11 256; CDC42BPB gene), cg12325605 (P = 5.24 × 10-09; n = 11 256; ARHGEF3 gene), and an intergenic CpG site cg14023999 (P = 5.99 × 10-08; n = 11 256; chromosome = 15q26.1). The predicted expression of the CDC42BPB gene in the brain (basal ganglia) (effect, 0.14; P = 2.7 × 10-03) and of ARHGEF3 in fibroblasts (effect, -0.48; P = 9.8 × 10-04) was associated with major depression. Conclusions and relevance: This study identifies 3 methylated sites associated with depressive symptoms. All 3 findings point toward axon guidance as the common disrupted pathway in depression. The findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression. Further research is warranted to determine the utility of these findings as biomarkers of depression and evaluate any potential role in the pathophysiology of depression and their downstream clinical effects.

DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies

The Associations Between DNA Methylation and Depression: A Systematic Review and Meta-Analysis

Investigating the Epigenetic Landscape of Major Depressive Disorder: A Genome-Wide Meta-Analysis of DNA Methylation Data, Including New Insights into Stochastic Epigenetic Mutations and Epivariations

Convergence of Evidence from a Methylome-Wide CpG-SNP Association Study and GWAS of Major Depressive Disorder

What do DNA methylation studies tell us about depression? A systematic review

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

Genome-wide DNA methylation and gene expression analyses in monozygotic twins identify potential biomarkers of depression

Epigenome-Wide Association Study of Depressive Symptoms in Black Women in the InterGEN Study

DNA methylation differences in stress-related genes, functional connectivity and gray matter volume in depressed and healthy adolescents

A review of DNA methylation in depression

Epigenome-wide Meta-Analysis of Blood DNA Methylation and Its Association with Subcortical Volumes: Findings from the ENIGMA Epigenetics Working Group

Genome-wide profiling of DNA methylome and transcriptome in peripheral blood monocytes for major depression: A Monozygotic Discordant Twin Study

Multi-Omics Integration Reveals Transcriptomic and Epigenetic Signatures Underlying Brain Structural Deficits in Major Depressive Disorder

Decoding depression: a comprehensive multi-cohort exploration of blood DNA methylation using machine learning and deep learning approaches

Genome-wide meta-analysis of ascertainment and symptom structures of major depression in case-enriched and community cohorts

DNA methylation in depression and depressive-like phenotype: biomarker or target of pharmacological intervention?

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

A Genome-Wide Association Study of Depressive Symptoms

DNA methylation and single nucleotide variants in the brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) genes are associated with anxiety/depression in older women

Integrated Analysis of Methylomic and Transcriptomic Data to Identify Potential Diagnostic Biomarkers for Major Depressive Disorder

Neuroimaging and epigenetic analysis reveal novel epigenetic loci in major depressive disorder